Abdominal Pain. Other and unspecified abdominal pain
Conditions
Interventions
Intervention 1: The first group (case group) was given probiotic from Lactobacillus family and Reuteri strain (BioGaia® brand manufactured by Sweden Health Care company) with dose 5 drops per day oral
Treatment - Drugs
The first group (case group) was given probiotic from Lactobacillus family and Reuteri strain (BioGaia® brand manufactured by Sweden Health Care company) with dose 5 drops per day orally equivalent of
The second group (control group) was given placebo with dose 5 drops per day orally for 4 weeks.
Sponsors
Zanjan University of Medical Science
Eligibility
Sex/Gender
All
Age
4 Years to 16 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria include: All children aged 4 to 16 years with functional abdominal pain (FAP) according to Rome III diagnostic criteria Exclusion criteria include: Have an abdominal pain with known organic cause; history of abdominal and gastrointestinal surgery; FTT or weight loss more than 5% of body weight; any abnormal paraclinical evaluations and history of drug use in the past 3 months (including antidepressants or laxatives).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of abdominal pain. Timepoint: Baseline, one month after starting treatment and one month after discontinuing the drugs. Method of measurement: numbers of pain episode per month recorded.;Intensityof abdominal pain. Timepoint: Baseline, one month after starting treatment and one month after discontinuation of the treatment. Method of measurement: Pain intensity was assessed according to the Wong-Baker faces scale systems. | — |
Secondary
| Measure | Time frame |
|---|---|
| Assoiated Sign. Timepoint: Baseline, one month after starting treatment and one month after discontinuing the drugs. Method of measurement: Based on history and clinical examination.;Side Effects and complication. Timepoint: Baseline, one month after starting treatment and one month after discontinuing the drugs. Method of measurement: Based on history and clinical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKambiz Eftekhari
Zanjan University of medical Science
Outcome results
None listed